Table. 2.

Risk factors associated with seropositivity 3 weeks after COVID-19 mRNA vaccination in solid organ transplant recipients

Variable Univariable analysis Multivariable analysisa)


OR (95% CI) P-value Adjusted OR (95% CI) P-value
Age ≥60 yr 0.81 (0.24–3.25) 0.75 - -
Male sex 1.20 (0.39–3.53) 0.75 - -
GFR (mL/min/1.73 m2)
≥30 & <45 0.48 (0.11–2.46) 0.33 - -
45≤ Reference Reference - -
Years from transplant
≤3 Reference Reference Reference Reference
>3 6.43 (1.64–42.9) 0.02 4.18 (0.66–36.73) 0.15
ABO-incompatible transplant 0.81 (0.24–3.25) 0.75 - -
Rituximab use within 1 yr 0.24 (0.06–0.97) 0.04 1.19 (0.16–10.57) 0.87
High-dose steroid use within 1 yr 0.36 (0.12–1.06) 0.07 1.37 (0.28–7.39) 0.70
Basiliximab or anti-thymocyte globulin use within 1 yr 0.19 (0.06–0.59) 0.004 0.56 (0.10–2.92) 0.49
Maintenance immunosuppressant
Tacrolimus serum concentration ≥8 ng/mL 1.02 (0.22–7.24) 0.98 - -
Steroid 0.26 (0.08–0.86) 0.03 0.37 (0.07–1.98) 0.24
Mycophenolic acid 0.06 (0.00–0.35) 0.01 0.06 (0.00–0.39) 0.02
mTOR inhibitor 1.88 (0.45-12.84) 0.44 - -
Vaccination regimen
Heterologous booster Reference Reference - -
Homologous booster 1.18 (0.24–4.49) 0.82 - -
Booster vaccine
mRNA-1273 Reference Reference - -
BNT162b2 2.80 (0.87–8.80) 0.08 3.45 (0.72–17.69) 0.12
Interval between second and third doses >3 mo 1.29 (0.06-10.88) 0.83 - -

COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; GFR, glomerular filtration rate; mTOR, mammalian target of rapamycin.

a)Tjur’s R2=0.30.

Korean J Transplant 2023;37:49~56 https://doi.org/10.4285/kjt.22.0056
© Clin Transplant Res